Magnolia Medical has announced the introduction of Magnolia Analytics, a technology-enabled service solution designed to streamline data capture and assess the clinical and cost-effectiveness of sepsis misdiagnosis prevention.
Developed in collaboration with several hospital systems in the US, the end-to-end, software-driven solution is aimed at supporting hospitals and healthcare systems in achieving the new national standard of care for blood culture contamination performance.
The Magnolia Analytics platform is a response to the need for robust quantification of the clinical and economic value created by reducing blood culture contamination.
This aligns with the recent CDC guidelines, which emphasise the importance of accurate sepsis testing for patient safety and hospital financial efficiency.
Magnolia Medical CEO and co-founder Greg Bullington said: “In response to our customer's clear unmet needs, we developed Magnolia Analytics as a custom, exclusive solution to support our hospitals in achieving and sustaining their blood culture contamination rates in line with the new benchmarks established by CDC and CLSI.
“The continued adoption of Steripath and Magnolia Medical's Mission to ZERO programme at nearly 500 hospitals and healthcare systems to date across the US speaks to the impact of our technology solution. The addition of Magnolia Analytics enables transparent access to performance monitoring for hospital leadership.”
Serving as the objective source, the platform can help in assessing the performance of unproven devices and interventions. This allows hospital systems to conduct an in-depth analysis of these solutions at the facility and patient level.
Bullington added: “Magnolia Analytics is an essential part of our Mission to ZERO solution, providing clinicians with confidence regarding the accuracy of blood culture results while giving our customers peace of mind that they will continually achieve validated, measurable, and sustained returns on their Steripath investment.”
Last year, Magnolia Medical secured 510(k) clearance from the US Food and Drug Administration for 19 new Steripath Micro configurations within its Initial Specimen Diversion Device product family.
